Summary

The AI Act: Progressing Faster Than Expected

The European Parliament is scheduled to vote on the legislation March 13, and one of the lawmakers leading the legislation said he expects it to pass easily. Under the current timeline the law would largely take effect in 2026, although some provisions would kick in this year.

The EU Parliament has rescheduled its vote to March 13, a full month sooner than originally planned. According to statements from Members of Parliament, the parliamentary vote is expected to closely mirror the committee's decision. The Act is anticipated to be approved by a significant majority of the members.

Next Steps: Following the Parliament's vote, the Council, consisting of governments from EU member states, will officially approve the Act. According to the present schedule, the law is set to come into full effect by 2026, though certain elements may be implemented as early as this year.

Overview of the Act:

  • The Act aims to categorize AI applications according to their risk level, imposing bans on specific applications such as "emotion recognition" in workplaces, which could lead to the highest penalties: either 7% of worldwide revenue or 35 million euros (approximately $38 million), whichever is greater.
  • The legislation will affect companies operating within the 27-country bloc and developers of AI systems used in the EU, regardless of their location, including those in the USA.
  • Any company that introduces a product to the EU market will need to comply with the AI Act, meaning its products must adhere to the regulations set forth by the Act.

Click here to read more

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified

Home

Discover our latest articles

View All Blog Posts
March 12, 2025
Clinical Trials
Biotech & Healthtech
Data Transfers
Regulations & Guidelines
Clinical Trial Sponsor

Navigating Privacy Requirements for Clinical Trials Across Jurisdictions: Focus on China

China’s data protection regulations play a crucial role in clinical trials, requiring sponsors and researchers to comply with multiple laws, including the PIPL, GCP-2020, and cross-border data transfer rules. Unlike other jurisdictions, China imposes strict consent requirements, risk assessments, and regulatory filings, making compliance a key factor when selecting trial locations and managing participant data.

October 14, 2024
Clinical Trials
Guideline

Analyzing the Similarities and Differences Between ICH-GCP and GDPR in Clinical Trials

ICH-GCP and GDPR are vital for clinical trials, setting standards for participant protection and data integrity, with distinct focuses and enforcement approaches.